A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

To join this study, you need to be at least 18 years old. You must have been diagnosed with a specific type of blood cancer called B-cell Non-Hodgkin Lymphoma, and your cancer needs to have come back or not responded well to at least two previous treatments. If your cancer is a specific type called Follicular Lymphoma, you might be able to join after just one previous treatment if it’s needed.

Your general health and physical ability to carry out daily activities will be assessed. Doctors will also need to see that your cancer is active and can be measured using scans like PET/CT. You'll also need to have healthy blood counts and other lab results, and provide a recent sample of your tumor tissue.

If you have a type of NHL called DLBCL and have only had one previous treatment, you might qualify if you can't have or have chosen not to have certain other standard treatments like a stem cell transplant or CAR T-cell therapy.

This information isn't fully detailed in the brief summary. However, typically, taking part in a study like this would involve regular visits to the clinic for check-ups, blood tests, and scans to monitor your health and how the treatment is working. You would receive the study medications, which might be given as injections under the skin (SC) or into a vein (IV). You would also likely have specific appointments for doctor consultations and to discuss any side effects. The total length of your participation would depend on the study design and your individual response to treatment, but trials often involve an initial treatment period followed by a follow-up phase. You would receive full details of the schedule if you were considering joining.